Mad Money with Jim Cramer - MAD CAP RECAP - The Official Mad Money Blog

HOME

CRAMERICAN CHALLENGE

BIO

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with the Madcap Recap blog.

FEATURED SLIDESHOW

  Who Is The Worst CEO?
Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
  nominations.

MAD MONEY FEATURES

PODCASTS
Watch the Lightning Round whenever and wherever you want.

OFFICIAL MAD MONEY WIDGET
Grab this all-in-one application and get recaps of the show sent right to your desktop or blog.

CRAMERS SOUNDBOARD
Admit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.

CHECK OUT OUR PHOTOS
Check out Cramer on set, back to school, behind the scenes and more.

SHOP FOR MAD MERCHANDISE
Buy Cramer books, bobbleheads and other Mad Money merchandise.

RING TONES
Pick up the phone! It's Cramer! New Mad Money sounds for your cell phone.

TEXT MESSAGE ALERT
Mad Money's mobile. Get show highlights sent to your phone.

Mad Mail: Buy the Berkshire Hathaway Split?

Published: Monday, 9 Nov 2009 | 9:49 PM ET

Text Size

By: Tom Brennan
Web Editor, Mad Money

Cramer started Monday’s Mad Mail by revisiting three stocks that stumped him during previous Lightning Rounds. He gave the thumbs-down to American Capital Agency [AGNC Loading... () ], saying the 19% dividend yield was a red flag. Also, the Federal Reserve could threaten the company’s profits if it decides to increase interest rates. American Capital Agency makes its money through the difference between the rate at which it borrows and the interest it earns on its mortgage-backed securities. A Fed move then could crush the stock.

Cramer's 8 Stocks for Cancer's Cure

Fuqi International [FUQI Loading... () ], on the other hand, is a good way to speculate on the growing Chinese middle class. This small $645 million jewelry maker holds a strong balance sheet and is up 580% since the March lows. Still, the stock trades at just eight times 2011 earnings. Fuqi took a hit after announcing a short fall in revenues, but regardless Cramer said he thought it was “a pretty solid quarter.”

Lastly, Cramer called Genomic Health [GHDX Loading... () ] “a very speculative cancer diagnostics play.” The company makes genomic-based clinical lab services for cancer that allow doctors and patients to make individual treatment decisions. One test, which quantifies the likelihood of disease recurrence in women with early-stage breast cancer, is now widely covered by health insurance, and another test for colorectal cancer is due out early in 2010. GHDX just reported a strong quarter, and there’s an analyst meeting on Thursday, Nov. 12. Cramer recommended waiting to hear more from that meeting before rushing to buy the stock.

___

Hi Jim!: My sister showed me the "booyah light" and I think you are doing a great job educating investors. In addition, I liked the cancer research spotlight as I am in remission for cancer. I was diagnosed in November of 2002 with a low-end cancer and I have my last Radioiodine treatment the first week of December! I have always wondered what stocks I could follow that have a bearing on my condition, so thank you. --Jim in New York

Cramer says: “I hope that everything goes well, sir … we are going to revisit all of these companies as we get closer to that hematology conference [on Dec. 5]. It’s just too compelling and cogent for many of you out there.”

___

Jim: My question for you is about Berkshire Hathaway [BRK.B Loading... () ]. In the past, because of the high price for a single share, this is not a stock that many could ever consider owning. However, due to the upcoming 50-for-1 split, is it now a stock that can be considered? Thank you for all you do. --David in Florida